Studienlage · Detail
Gemischt
GRADE
Moderat
248 Zitate
Stichproben = 15 Pat.
Dauer3 separate occasions
KontrollePlacebo
EndpunktBOLD-Antwort
Verblindungdoppelblind
DesignRCT
Cannabinoidkombination
Max. Dosis610.0 mg
Applikationoral
Kernaussage
Δ9-THC erhöhte psychotische Symptome, Angst und Sedation, modifizierte Hirnaktivierung in Parahippocampus und Ventrostriatum, beeinträchtigte jedoch nicht signifikant die Lernleistung; Cannabidiol zeigte keine derartigen Effekte.
Zusammenfassung
n=15 gesunde Probanden, THC-induzierte Modulation mediotemporaler und ventrostriataler Funktion mittels fMRI; THC modulierte Aktivität in Hippocampus und ventralem Striatum, Regionen relevant für Psychose-Pathophysiologie.
P
PopulationGesunde männliche Erwachsene (englischsprachig, rechtshändig, weiß) mit minimaler Cannabis-Exposition (≤15 Gelegenheiten), n=15
I
InterventionΔ9-Tetrahydrocannabinol (10 mg oral) und Cannabidiol (600 mg oral), jeweils als Einzeldosis
C
KontrollePlacebo
O
OutcomeΔ9-THC erhöhte psychotische Symptome, Angst und Intoxikation signifikant; verstärkte parahippocampale Aktivierung während Enkodierung (Blocks 2+3) und attenuierte ventrostriatale Aktivierung während Abruf (korreliert mit Psychose-Symptomen). Cannabidiol zeigte keine signifikanten Effekte. Verbale Lernleistung unverändert.
Vertrauen in die Evidenz
Moderat
Dritte von vier GRADE-Stufen, die Effektschätzung ist wahrscheinlich verlässlich.
Herabgestuft wegen
Ungenauigkeit
Qualitätsprofil
Größe
★★★★★
Verblindung
Doppelblind
Effektstärke
Gemischt
Zitate / Jahr
★★★★★
Autoren
Teilen
Abstract
Context: Cannabis sativa use can impair verbal learning, provoke acute psychosis, and increase the risk of schizophrenia. It is unclear where C. sativa acts in the human brain to modulate verbal learning and to induce psychotic symptoms.
Objectives: To investigate the effects of 2 main psychoactive constituents of C. sativa, Delta9-tetrahydrocannabinol (Delta9-THC) and cannabidiol, on regional brain function during verbal paired associate learning.
Design: Subjects were studied on 3 separate occasions using a block design functional magnetic resonance imaging paradigm while performing a verbal paired associate learning task. Each imaging session was preceded by the ingestion of Delta9-THC (10 mg), cannabidiol (600 mg), or placebo in a double-blind, randomized, placebo-controlled, repeated-measures, within-subject design.
Setting: University research center.
Participants: Fifteen healthy, native English-speaking, right-handed men of white race/ethnicity who had used C. sativa 15 times or less and had minimal exposure to other illicit drugs in their lifetime.
Main Outcome Measures: Regional brain activation (blood oxygen level-dependent response), performance in a verbal learning task, and objective and subjective ratings of psychotic symptoms, anxiety, intoxication, and sedation.
Results: Delta9-Tetrahydrocannabinol increased psychotic symptoms and levels of anxiety, intoxication, and sedation, whereas no significant effect was noted on these parameters following administration of cannabidiol. Performance in the verbal learning task was not significantly modulated by either drug. Administration of Delta9-THC augmented activation in the parahippocampal gyrus during blocks 2 and 3 such that the normal linear decrement in activation across repeated encoding blocks was no longer evident. Delta9-Tetrahydrocannabinol also attenuated the normal time-dependent change in ventrostriatal activation during retrieval of word pairs, which was directly correlated with concurrently induced psychotic symptoms. In contrast, administration of cannabidiol had no such effect.
Conclusion: The modulation of mediotemporal and ventrostriatal function by Delta9-THC may underlie the effects of C. sativa on verbal learning and psychotic symptoms, respectively.
„Was dem Handeln im Weg steht, wird zum Weg.“